Single B-cell screening and hybridoma technology represent two fundamentally different approaches to isolating therapeutic antibody candidates, each with distinct trade-offs in speed, diversity, and hit quality. Understanding which method fits your program’s biology, timeline, and downstream requirements is a decision that shapes everything from lead quality to IND readiness.
What is hybridoma technology and how does it work?
Hybridoma technology, first described by Köhler and Milstein in 1975, produces monoclonal antibodies by fusing antibody-secreting B cells from an immunized animal with immortal myeloma cells to create stable, continuously dividing cell lines. Each hybridoma clone secretes a single, defined antibody, enabling scalable production from a renewable source. The approach enabled the first approved antibody drug, Muromonab-CD3, in 1985, and established the foundational logic of monoclonal antibody discovery that the field still builds on today.
The core limitation is throughput and speed. Hybridoma workflows are slow and cumbersome, requiring weeks of cell fusion, selection, and subcloning before a confirmed monoclonal sequence is in hand. Sequence recovery also depends on downstream cloning from the hybridoma cell line, introducing additional steps and the risk of sequence drift.
What is single B-cell screening and how does it differ from hybridoma?
Single B-cell screening isolates individual antigen-specific B cells directly from immunized animals and recovers their antibody sequences without a cell fusion step. Platforms such as the Beacon® system enable function-based assays at the single-cell level, identifying hits based on binding, blocking, or functional activity before any sequence is committed to expression.
The practical difference is speed and information density. Single B-cell methods compress the timeline from immunization to confirmed sequence, and they preserve the native heavy-light chain pairing of each B cell, which hybridoma subcloning can disrupt. Function-based screening at the single-cell stage also means that hits are selected on the biology that matters, not just on expression level from a fused cell line.
How do the two methods compare on key discovery parameters?
|
Parameter |
Hybridoma |
Single B-Cell Screening (e.g., Beacon®) |
|---|---|---|
|
Throughput |
Low to moderate |
High; thousands of cells per run |
|
Timeline to confirmed sequence |
Weeks to months |
Days to weeks |
|
Native chain pairing preserved |
Risk of drift during subcloning |
Yes, recovered directly from single cell |
|
Function-based selection |
Limited; post-hoc screening |
Yes; assay at point of isolation |
|
Sequence diversity captured |
Moderate |
High; samples broader repertoire |
|
Applicability to HCAb formats |
Standard |
Compatible with both H2L2 and HCAb |
Is the Beacon® platform the same as single B-cell screening?
The Beacon® platform is one instrument used to execute single B-cell screening, but the two terms are not interchangeable. Single B-cell screening is the broader methodology; the Beacon® is a specific optofluidic system that enables high-throughput, function-based assays on individual cells in nanoliter-scale chambers.
Owning a Beacon® instrument does not automatically confer expertise. The platform carries a notoriously high learning curve, requiring one to two years for a team to become fully proficient. Nona Biosciences was an early adopter of the Beacon® system, and that accumulated operational depth, not hardware access alone, is what translates into reliable hit rates and reproducible data for clients.
When should a program choose single B-cell screening over hybridoma?
Single B-cell screening is the preferred choice when speed, sequence diversity, or function-based selection is a priority. Programs targeting difficult antigens, rare epitopes, or functional blocking activity benefit most from the ability to screen thousands of individual B cells against a defined assay before committing to expression. For programs where the antibody format is a heavy-chain-only antibody (HCAb), single B-cell approaches are particularly well-suited because HCAb sequences are encoded by a single gene, simplifying recovery and downstream processing.
Hybridoma remains a reasonable option when the program requires a well-established, widely accepted workflow and the timeline is not the primary constraint. Some regulatory and manufacturing teams have deep familiarity with hybridoma-derived cell lines, and for certain antigen types, the fusion efficiency is sufficient to generate adequate diversity. The decision should be driven by the target biology, not by default.
What is the difference between fully human and humanized antibodies, and does the screening method affect this?
Fully human antibodies carry 100% human sequence, produced in vivo through natural immune selection. Humanized antibodies are non-human sequences that have been engineered to replace framework regions with human equivalents, but they retain residual non-human residues and carry the engineering trade-offs that come with CDR grafting. This distinction matters clinically: fully human sequences are inherently more compatible with human immune tolerance, while humanized sequences carry residual immunogenicity risk.
Understanding the difference between fully human and humanized antibodies is critical when selecting the appropriate discovery platform. Combining Harbour Mice® with single B-cell screening on the Beacon® platform captures the benefits of both: fully human sequence origin and function-based, high-throughput hit selection.
Can single B-cell screening be used for heavy-chain-only antibody (HCAb) discovery?
Single B-cell screening is fully compatible with HCAb discovery from Harbour Mice®. HCAb VH domains are encoded by a single gene, which simplifies sequence recovery from individual B cells compared to H2L2 formats that require correct heavy-light chain pairing to be maintained through the isolation process.
Nona’s fully human antibody discovery workflows integrate Harbour Mice® immunization with Beacon®-based single B-cell screening to recover HCAb hits with sub-nanomolar to low nanomolar affinities. The single-domain nature of VH domains also enables high-yield expression in both microbial and mammalian systems, including CHO cells, streamlining the path from hit to lead.
How does throughput compare between hybridoma and Beacon®-based single B-cell screening?
Beacon®-based single B-cell screening operates at a throughput level that hybridoma cannot match. The Beacon® platform enables screening of thousands of individual B cells per run with function-based assays, while hybridoma workflows are constrained by fusion efficiency and the time required to expand and subclone individual wells.
For programs where repertoire coverage is critical, such as those targeting conserved epitopes across variants or seeking rare functional blockers, the throughput advantage of single B-cell screening directly translates into a higher probability of identifying the best possible lead. Nona’s Beacon® single B-cell screening service applies this throughput advantage within an integrated discovery workflow that connects hit identification directly to lead characterization and engineering.
Does Nona Biosciences offer hybridoma as well as single B-cell screening?
Nona offers hybridoma as part of a comprehensive suite of screening technologies that also includes Beacon®-based single B-cell screening, phage display, yeast display, and the proprietary NonaCarFx™ platform. Nona’s scientific team identifies the method best matched to the target’s biology, rather than defaulting to a specific platform.
For most therapeutic antibody programs, single B-cell screening on the Beacon® platform is the recommended starting point because of its speed, function-based selection capability, and compatibility with both H2L2 and HCAb formats from Harbour Mice®. Hybridoma remains available for programs where it is the scientifically appropriate choice. Across more than 300 completed antibody discovery programs, Nona has generated 19+ clinical-stage molecules, a track record that reflects the value of matching the right screening method to each program’s specific requirements.
What comes after hit identification, regardless of which screening method is used?
Hit identification is the beginning of the discovery process, not the end. Whether hits are recovered by hybridoma or single B-cell screening, they require confirmation, affinity characterization, selectivity profiling, and developability assessment before a lead can be nominated for IND-enabling studies.
Nona’s I-to-I® (integrated end-to-end service pathway from ideation through IND filing) connects hit identification directly to antibody engineering, developability assessment, and preclinical evaluation within a single integrated workflow. Early-stage developability screening, covering expression yield, thermal stability, aggregation resistance, and chemical liabilities, is built into the pipeline to minimize late-stage attrition and reduce the risk of costly re-engineering cycles downstream.
If your program is at the stage of selecting a screening strategy, Nona’s scientific team can evaluate your target biology, format requirements, and timeline to recommend the approach most likely to deliver high-quality leads efficiently. Reach out to discuss your discovery program and how our integrated platform can accelerate your path from immunization to IND.
-
G. Köhler and C. Milstein, Continuous cultures of fused cells secreting antibody of predefined specificity, Nature, 1975. Link
-
J. Tiller et al., Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning, Journal of Immunological Methods, 2008. Link
-
L. Corti and A. Lanzavecchia, Efficient methods to isolate human monoclonal antibodies from memory B cells and plasma cells, Microbiology Spectrum, 2014. Link
-
A. Traggiai et al., An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus, Nature Medicine, 2004. Link
-
D. Seeber et al., Comparison of hybridoma and single B cell technologies for the generation of monoclonal antibodies, Antibody Therapeutics, 2020. Link
-
H. Wardemann and A. Busse, Novel approaches to analyze immunoglobulin repertoires, Trends in Immunology, 2017. Link
